Zhejiang Jianfeng Group Subsidiary Receives Regulatory Nod for Antihypertensive Active Ingredient

Stock News15:41

Zhejiang Jianfeng Group Co.,Ltd. (SH: 600668) has announced that its subsidiary has obtained official approval for the market entry of a key pharmaceutical raw material.

According to the company's recent disclosure, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., a subsidiary of the group, has received the "Chemical Raw Material Drug Marketing Authorization Approval Notice" (Notice No. 2026YS00812) from China's National Medical Products Administration for the active pharmaceutical ingredient Methyldopa.

Methyldopa, originally developed by Merck Sharp & Dohme (MSD) and approved by the U.S. FDA in 1962, stands as the world's first-generation centrally acting antihypertensive agent. As a prodrug, it crosses the blood-brain barrier after oral absorption and is metabolized centrally into alpha-methylnorepinephrine, a false neurotransmitter. This metabolite stimulates alpha-2 adrenergic receptors in the brainstem, suppresses sympathetic outflow, and reduces peripheral vascular resistance to achieve blood pressure reduction. The drug remains a classic first-line therapeutic option for hypertension during pregnancy.

This approval marks a significant regulatory milestone for the subsidiary, positioning it to contribute to the production and supply of this established therapeutic compound.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138322708?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 15:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138322708","market":"other","top_or_hot":-1,"title":"Zhejiang Jianfeng Group Subsidiary Receives Regulatory Nod for Antihypertensive Active Ingredient","media":"Stock News","content":"<p><b>Zhejiang Jianfeng Group Co.,Ltd.</b> (SH: 600668) has announced that its subsidiary has obtained official approval for the market entry of a key pharmaceutical raw material.<br><br>According to the company's recent disclosure, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., a subsidiary of the group, has received the \"Chemical Raw Material Drug Marketing Authorization Approval Notice\" (Notice No. 2026YS00812) from China's National Medical Products Administration for the active pharmaceutical ingredient Methyldopa.<br><br>Methyldopa, originally developed by Merck Sharp & Dohme (MSD) and approved by the U.S. FDA in 1962, stands as the world's first-generation centrally acting antihypertensive agent. As a prodrug, it crosses the blood-brain barrier after oral absorption and is metabolized centrally into alpha-methylnorepinephrine, a false neurotransmitter. This metabolite stimulates alpha-2 adrenergic receptors in the brainstem, suppresses sympathetic outflow, and reduces peripheral vascular resistance to achieve blood pressure reduction. The drug remains a classic first-line therapeutic option for hypertension during pregnancy.<br><br>This approval marks a significant regulatory milestone for the subsidiary, positioning it to contribute to the production and supply of this established therapeutic compound.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Jianfeng Group Subsidiary Receives Regulatory Nod for Antihypertensive Active Ingredient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Jianfeng Group Subsidiary Receives Regulatory Nod for Antihypertensive Active Ingredient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-01 15:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Zhejiang Jianfeng Group Co.,Ltd.</b> (SH: 600668) has announced that its subsidiary has obtained official approval for the market entry of a key pharmaceutical raw material.<br><br>According to the company's recent disclosure, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., a subsidiary of the group, has received the \"Chemical Raw Material Drug Marketing Authorization Approval Notice\" (Notice No. 2026YS00812) from China's National Medical Products Administration for the active pharmaceutical ingredient Methyldopa.<br><br>Methyldopa, originally developed by Merck Sharp & Dohme (MSD) and approved by the U.S. FDA in 1962, stands as the world's first-generation centrally acting antihypertensive agent. As a prodrug, it crosses the blood-brain barrier after oral absorption and is metabolized centrally into alpha-methylnorepinephrine, a false neurotransmitter. This metabolite stimulates alpha-2 adrenergic receptors in the brainstem, suppresses sympathetic outflow, and reduces peripheral vascular resistance to achieve blood pressure reduction. The drug remains a classic first-line therapeutic option for hypertension during pregnancy.<br><br>This approval marks a significant regulatory milestone for the subsidiary, positioning it to contribute to the production and supply of this established therapeutic compound.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1138322708","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138322708","pubTimestamp":1788248466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Jianfeng Group Co.,Ltd. (SH: 600668) has announced that its subsidiary has obtained official approval for the market entry of a key pharmaceutical raw material.According to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"浙江尖峰集团子公司抗高血压活性成分获监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600668":1,"IPOS":1},"content_text":"Zhejiang Jianfeng Group Co.,Ltd. (SH: 600668) has announced that its subsidiary has obtained official approval for the market entry of a key pharmaceutical raw material.According to the company's recent disclosure, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., a subsidiary of the group, has received the \"Chemical Raw Material Drug Marketing Authorization Approval Notice\" (Notice No. 2026YS00812) from China's National Medical Products Administration for the active pharmaceutical ingredient Methyldopa.Methyldopa, originally developed by Merck Sharp & Dohme (MSD) and approved by the U.S. FDA in 1962, stands as the world's first-generation centrally acting antihypertensive agent. As a prodrug, it crosses the blood-brain barrier after oral absorption and is metabolized centrally into alpha-methylnorepinephrine, a false neurotransmitter. This metabolite stimulates alpha-2 adrenergic receptors in the brainstem, suppresses sympathetic outflow, and reduces peripheral vascular resistance to achieve blood pressure reduction. The drug remains a classic first-line therapeutic option for hypertension during pregnancy.This approval marks a significant regulatory milestone for the subsidiary, positioning it to contribute to the production and supply of this established therapeutic compound.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138322708","isCrawlerRequest":true}